China Approves World's First Invasive Brain-Computer Interface: What the NEO Chip Means for the Future

A Historic Moment in Neurotechnology: China's NEO Brain Chip Gets the Green Light

In a quiet courtyard in China's Henan province last October, a 39-year-old man named Dong Hui picked up a pen and slowly, carefully, wrote his own name. For most people, this would be an unremarkable act. For Dong — who had been paralyzed from the neck down following a spinal cord injury sustained in a car accident six years prior — it was nothing short of a miracle. What made it possible was a small device implanted inside his brain, and the eleven months of rigorous rehabilitation that followed. Before the implant, Dong could move his arms only slightly. He had no use of his fingers at all.

"I couldn't believe I was able to write again. I was so excited I even missed a stroke in my name," Dong told MIT Technology Review in a video call.

Dong's story is not just a personal triumph. It represents a technological and regulatory milestone that is reshaping the global landscape of neuroscience: China has officially approved the world's first invasive brain-computer interface (BCI) for use beyond clinical trials.

What Is the NEO Chip and Who Made It?

The device at the center of this breakthrough is called NEO — a coin-sized implant developed by Neuracle Technology, a startup based in Shanghai. Unlike non-invasive BCIs that sit outside the skull, the NEO chip is surgically implanted directly into the brain, allowing it to detect neural signals with far greater precision and resolution. This makes it especially effective for patients with severe paralysis, enabling them to regain motor function through a combination of neural decoding and physical rehabilitation.

Neuracle Technology's NEO has beaten some of the most well-funded names in the industry — including Elon Musk's Neuralink — to become the first invasive BCI formally approved for use in a real-world, non-trial medical setting. As of late 2024, the device is now available to paralysis patients across China, with Dong Hui among the first beneficiaries of this approval.

Why China Is Moving So Fast on Brain Technology

The rapid approval of the NEO chip did not happen in isolation. It reflects a deliberate, state-level strategy. Beijing has moved aggressively to position China as a global leader in neurotechnology, and the evidence is hard to ignore.

• The NEO chip has been fast-tracked into China's national health insurance system, dramatically reducing the cost barrier for patients who need it.
• Beijing has officially designated the brain-computer interface industry as one of six sectors critical to China's future economic and technological development.
• Government funding, regulatory prioritization, and institutional support have combined to create an environment where neurotechnology can move from laboratory to patient faster than almost anywhere else in the world.

Experts note that there is no comparable national-level ambition in this space anywhere else on the planet. While other governments talk about the potential of brain-computer interfaces, China is acting on it — at scale, and with urgency.

How Does the NEO BCI Actually Work?

At its core, a brain-computer interface works by reading the electrical signals generated by neurons in the brain and translating them into commands that can control external devices or, in therapeutic applications like Dong's case, stimulate physical movement through targeted rehabilitation. Invasive BCIs like NEO do this by placing electrodes directly on or within brain tissue, providing a much cleaner and more detailed signal than non-invasive alternatives such as EEG headsets.

In Dong's case, the implant helped decode his motor intentions — the neural signals his brain was generating even when his body could not respond — and used those signals to guide a rehabilitation program that ultimately restored meaningful hand function. This approach, which combines neural signal decoding with intensive physical therapy, represents one of the most promising frontiers in treating spinal cord injuries and other forms of paralysis.

The US vs. China: Two Very Different Races

It would be tempting to frame the NEO approval as China "winning" a race against companies like Neuralink, Synchron, or Precision Neuroscience. But experts caution against this framing. The US and China are, in many ways, playing entirely different games.

The United States remains focused on pushing the boundaries of what is scientifically possible — high-risk, high-reward breakthroughs that could eventually transform human cognition, communication, and medicine. Neuralink, for example, is pursuing ambitious long-term applications far beyond paralysis treatment.

China, meanwhile, is focused on scale and accessibility. The goal is not necessarily to make the most cutting-edge device, but to make a clinically effective device available to the largest number of patients as quickly as possible. Fast-tracking NEO into the national insurance system is a direct expression of this philosophy.

Interestingly, despite rising geopolitical tensions between the two countries, US-China collaboration in neurotechnology has not stopped entirely. American firm Axoft is already running clinical trials in Shanghai, suggesting that the scientific community — at least for now — continues to find value in cross-border cooperation even as political relations remain strained.

What Comes Next for Brain-Computer Interfaces?

The approval of NEO is a landmark, but it is also just the beginning. Several important questions will shape the next chapter of BCI development globally.

• Safety and long-term outcomes: Invasive BCIs require brain surgery, and the long-term effects of having foreign devices in neural tissue are still being studied. Regulatory bodies worldwide will be watching China's real-world outcomes data closely.
• Ethical considerations: As BCIs become more powerful and more widespread, questions about privacy, consent, cognitive enhancement, and equitable access will move to the forefront of public and policy debate.
• Regulatory pathways elsewhere: China's approval will put pressure on regulatory agencies in the US, Europe, and elsewhere to clarify and potentially accelerate their own pathways for BCI approval.
• Commercial expansion: With insurance coverage in place, Neuracle Technology is positioned to scale rapidly within China. Whether NEO or its successors eventually reach international markets remains to be seen.

A New Era for Patients — and for Humanity

For Dong Hui, the philosophical debates about geopolitics and regulatory strategy are secondary to a far more personal reality: he can write his name again. He can hold a pen. He can do something he thought was lost forever. That outcome — restoring agency and dignity to people living with paralysis — is the beating heart of the BCI revolution, wherever it happens to unfold.

China's approval of the NEO chip signals that we have crossed a threshold. Brain-computer interfaces are no longer a futuristic concept or an experimental curiosity reserved for a handful of trial participants. They are, for the first time, an officially sanctioned medical reality. The world is watching what happens next — and so, most importantly, are the millions of patients around the world who are waiting for technology to give them back what injury and illness took away.